Fierce Biotech
Biotech value creation at an inflection point
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Latest medical news · page 279
The latest headlines across every section, pulled from official and open-access sources.
Fierce Biotech
Biopharma IPOs: Timing, capital and staying flexible
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Fierce Biotech
Biopharma moves to reduce development risk earlier than ever
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
Fierce Biotech
Executive Interviews at Fierce Biotech Week 2026
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
Fierce Biotech
Why City of Hope Built a National Clinical Trials Platform Designed to Scale With Oncology Innovation
City of Hope built a national trials engine to move oncology innovation faster, wider and with the scale sponsors need.
Fierce Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
Fierce Biotech
ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Fierce Biotech
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog, petrelintide.
Fierce Biotech
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
Fierce Biotech
ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
Fierce Biotech
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
Fierce Biotech
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.
Fierce Biotech
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.
Fierce Biotech
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.
Fierce Biotech
CeQur nabs $100M series E to fuel insulin patch commercialization
Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”
Fierce Biotech
Roche sticks with €600M diagnostics investment in Germany but warns of future risk
As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.
Fierce Biotech
The new standard for trusted AI in biopharma
As costs climb, capital tightens and AI enthusiasm accelerates, biopharma leaders are rethinking how better decisions get made.
Fierce Biotech
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
Fierce Biotech
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers.
Fierce Biotech
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
ACC (Cardiology)
ACCEL Lite: Key Take-Home Messages From the 2025 Sports Cardiology Guidelines
In this interview, Alison L. Bailey, MD, FACC and Aaron Baggish, MD, FACC examine the latest sports cardiology guidelines.
Fierce Biotech
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market
Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.
Fierce Biotech
Fueled by M&A and partnerships, biotech is poised for continued growth: EY
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.
ACC (Cardiology)
Optimizing Dual Antiplatelet Therapy in Patients With Diabetes and Multivessel Disease Undergoing PCI: The TUXEDO-2 Trial
The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2—India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...